Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Carlsmed (CARL) Research & Development (2024 - 2025)

Carlsmed (CARL) has disclosed Research & Development for 2 consecutive years, with $11.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 24.62% year-over-year to $11.2 million, compared with a TTM value of $20.6 million through Dec 2025, changed N/A, and an annual FY2025 reading of $17.0 million, up 18.98% over the prior year.
  • Research & Development was $11.2 million for Q4 2025 at Carlsmed, up from -$1.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $11.2 million in Q4 2025 and bottomed at -$1.5 million in Q3 2025.